auto-fix: strip 4 broken wiki links
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base.
This commit is contained in:
Teleo Agents
parent
dc7058ab5a
commit
bb32e1968c
4 changed files with 4 additions and 4 deletions
|
|
@ -60,7 +60,7 @@ intake_tier: research-task
|
||||||
|
|
||||||
**KB connections:**
|
**KB connections:**
|
||||||
- [[medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials]] — analogous pattern: clinical benefit in trials doesn't translate to regulatory success if methodology is flawed
|
- [[medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials]] — analogous pattern: clinical benefit in trials doesn't translate to regulatory success if methodology is flawed
|
||||||
- [[healthcare AI regulation needs blank-sheet redesign]] — related but distinct: here the issue is trial methodology for a drug, not regulation of AI
|
- healthcare AI regulation needs blank-sheet redesign — related but distinct: here the issue is trial methodology for a drug, not regulation of AI
|
||||||
- Contrast with Compass Pathways archives (COMP005, COMP006) — psilocybin passed; MDMA failed; the methodology difference (active comparator vs. inert placebo) explains the divergence
|
- Contrast with Compass Pathways archives (COMP005, COMP006) — psilocybin passed; MDMA failed; the methodology difference (active comparator vs. inert placebo) explains the divergence
|
||||||
|
|
||||||
**Extraction hints:**
|
**Extraction hints:**
|
||||||
|
|
|
||||||
|
|
@ -64,7 +64,7 @@ intake_tier: research-task
|
||||||
|
|
||||||
**KB connections:**
|
**KB connections:**
|
||||||
- [[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]] — veterans' mental health is a specific, politically salient subset of the broader mental health supply gap
|
- [[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]] — veterans' mental health is a specific, politically salient subset of the broader mental health supply gap
|
||||||
- [[healthcare AI regulation needs blank-sheet redesign]] — ibogaine raises a different regulatory question: how do you conduct blinded trials for a drug with such profound psychoactive effects?
|
- healthcare AI regulation needs blank-sheet redesign — ibogaine raises a different regulatory question: how do you conduct blinded trials for a drug with such profound psychoactive effects?
|
||||||
- Connects to the MDMA-AT CRL archive: functional unblinding problem exists for ibogaine too; how will Phase 3 trials be designed?
|
- Connects to the MDMA-AT CRL archive: functional unblinding problem exists for ibogaine too; how will Phase 3 trials be designed?
|
||||||
|
|
||||||
**Extraction hints:**
|
**Extraction hints:**
|
||||||
|
|
|
||||||
|
|
@ -56,7 +56,7 @@ intake_tier: research-task
|
||||||
**KB connections:**
|
**KB connections:**
|
||||||
- DIRECTLY CHALLENGES: [[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]] — this claim is now temporally incorrect for 2024
|
- DIRECTLY CHALLENGES: [[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]] — this claim is now temporally incorrect for 2024
|
||||||
- COMPLICATES: Belief 1 grounding ("compounding failure") — the acute acute dimension is improving
|
- COMPLICATES: Belief 1 grounding ("compounding failure") — the acute acute dimension is improving
|
||||||
- CONNECTS TO: [[Big Food companies engineer addictive products by hacking evolutionary reward pathways]] — food-driven chronic disease threat remains even as drug deaths improve
|
- CONNECTS TO: Big Food companies engineer addictive products by hacking evolutionary reward pathways — food-driven chronic disease threat remains even as drug deaths improve
|
||||||
- CONNECTS TO: IHME 2050 forecast (structural metabolic threat persists)
|
- CONNECTS TO: IHME 2050 forecast (structural metabolic threat persists)
|
||||||
|
|
||||||
**Extraction hints:**
|
**Extraction hints:**
|
||||||
|
|
|
||||||
|
|
@ -66,7 +66,7 @@ intake_tier: research-task
|
||||||
**What I expected but didn't find:** Any reference to MDMA-AT specifically. Methylone (TSND-201, Transcend Therapeutics) received a voucher — this is an MDMA-like compound but a distinct chemical entity, addressing the MDMA regulatory failure by pursuing a related molecule with cleaner trial design.
|
**What I expected but didn't find:** Any reference to MDMA-AT specifically. Methylone (TSND-201, Transcend Therapeutics) received a voucher — this is an MDMA-like compound but a distinct chemical entity, addressing the MDMA regulatory failure by pursuing a related molecule with cleaner trial design.
|
||||||
|
|
||||||
**KB connections:**
|
**KB connections:**
|
||||||
- [[healthcare AI regulation needs blank-sheet redesign]] — by contrast, this EO uses EXISTING regulatory frameworks (Right to Try, priority review) rather than new ones
|
- healthcare AI regulation needs blank-sheet redesign — by contrast, this EO uses EXISTING regulatory frameworks (Right to Try, priority review) rather than new ones
|
||||||
- [[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]] — if psilocybin is approved, it creates a new category for the most treatment-resistant patients; but access will be clinic-based (not scalable)
|
- [[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]] — if psilocybin is approved, it creates a new category for the most treatment-resistant patients; but access will be clinic-based (not scalable)
|
||||||
- Belief 3: EO represents regulatory system responding to clinical evidence + political pressure — BUT: it's using expedited tools that may create safety risks if approval happens before adequate real-world evidence accumulates
|
- Belief 3: EO represents regulatory system responding to clinical evidence + political pressure — BUT: it's using expedited tools that may create safety risks if approval happens before adequate real-world evidence accumulates
|
||||||
|
|
||||||
|
|
|
||||||
Loading…
Reference in a new issue